STAAR Surgical Company STAA · NASDAQ
$22.61 +0.53% (+$0.12)
Summary
33 / 100 · Bulios Score
What speaks for it
- It holds more cash than debt: $148.6M against $35.9M.
- Analysts expect revenue to grow by 29% this fiscal year.
What to watch
- Revenue fell by 5.6% a year over the last 3 years.
- Out of every 100 USD of revenue, only 1.1 USD is left as net profit.
- It earns only 1.9 USD a year on every 100 USD of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveToday you pay 293.8 USD for 1 USD of yearly profit. Over the last five years it was 98.9 USD on average.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 7.9% a year over 5 years. Over the last 3 years it fell by 5.6% a year. For the next fiscal year analysts expect revenue to grow by 29%.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 24 USD
- Research and development 11 USD
- Sales and administration 55 USD
- Taxes and other 9.2 USD
- Net profit 1.1 USD
Net profit, industry median (Medical - Instruments & Supplies) 8.1 USD
Out of every 100 USD of revenue, 1.1 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesOver the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 5
- Hold 9
- Sell 2
Today's price within the analysts' price targets
The average target of $30.89 is 37% above today's price. 31% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2024By product
- Implantable Collamer Lenses 100%
- Other Surgical Products 0.4%
By region
- Other Countries 38%
- CHINA 37%
- JAPAN 19%
- UNITED STATES 5.9%
Implantable Collamer Lenses brings in 100% of revenue.
Segments in detail